{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:58:37Z","timestamp":1793750317851,"version":"4.6.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Zika virus (ZIKV), an arbovirus transmitted by mosquitoes, was identified as a cause of congenital disease during a major outbreak in the Americas in 2016. Vaccine design strategies relied on limited available isolate sequence information due to the rapid response necessary. The first-generation ZIKV mRNA vaccine, mRNA-1325, was initially generated and, as additional strain sequences became available, a second mRNA vaccine, mRNA-1893, was developed. Herein, we compared the immune responses following mRNA-1325 and mRNA-1893 vaccination and reported that mRNA-1893 generated comparable neutralizing antibody titers to mRNA-1325 at 1\/20th of the dose and provided complete protection from ZIKV challenge in non-human primates. In-depth characterization of these vaccines indicated that the observed immunologic differences could be attributed to a single amino acid residue difference that compromised mRNA-1325 virus-like particle formation.<\/jats:p>","DOI":"10.1038\/s41541-023-00656-4","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T18:03:44Z","timestamp":1682013824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection"],"prefix":"10.1038","volume":"8","author":[{"given":"Brooke","family":"Bollman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Nunna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Bahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8961-7522","authenticated-orcid":false,"given":"Chiaowen Joyce","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamilton","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryant","family":"Foreman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Burgomaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Aleshnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing-Pui","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian E.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0007-7169","authenticated-orcid":false,"given":"Tracy J.","family":"Ruckwardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4849-4690","authenticated-orcid":false,"given":"Kaitlyn M.","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barney S.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Dowd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore C.","family":"Pierson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"656_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.antiviral.2016.03.010","volume":"130","author":"SC Weaver","year":"2016","unstructured":"Weaver, S. C. et al. Zika virus: History, emergence, biology, and prospects for control. Antiviral Res. 130, 69\u201380 (2016).","journal-title":"Antiviral Res."},{"key":"656_CR2","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3201\/eid2006.140138","volume":"20","author":"VM Cao-Lormeau","year":"2014","unstructured":"Cao-Lormeau, V. M. et al. Zika virus, French polynesia, South pacific, 2013. Emerg. Infect. Dis. 20, 1085\u20131086 (2014).","journal-title":"Emerg. Infect. Dis."},{"key":"656_CR3","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJMp1602708","volume":"374","author":"N Broutet","year":"2016","unstructured":"Broutet, N. et al. Zika virus as a cause of neurologic disorders. N. Engl. J. Med. 374, 1506\u20131509 (2016).","journal-title":"N. Engl. J. Med."},{"key":"656_CR4","unstructured":"WHO. The history of Zika virus, https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-history-of-zika-virus (2016)."},{"key":"656_CR5","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1056\/NEJMoa1602412","volume":"375","author":"P Brasil","year":"2016","unstructured":"Brasil, P. et al. Zika virus infection in pregnant women in Rio de Janeiro. N. Engl. J. Med. 375, 2321\u20132334 (2016).","journal-title":"N. Engl. J. Med."},{"key":"656_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1473-3099(16)00095-5","volume":"16","author":"G Calvet","year":"2016","unstructured":"Calvet, G. et al. Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study. Lancet Infect. Dis. 16, 653\u2013660 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"656_CR7","doi-asserted-by":"publisher","first-page":"e0004517","DOI":"10.1371\/journal.pntd.0004517","volume":"10","author":"M Sarno","year":"2016","unstructured":"Sarno, M. et al. Zika virus infection and stillbirths: a case of hydrops fetalis, hydranencephaly and fetal demise. PLoS Negl. Trop. Dis. 10, e0004517 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"656_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.15585\/mmwr.mm6508e2","volume":"65","author":"SL Hills","year":"2016","unstructured":"Hills, S. L. et al. Transmission of Zika virus through sexual contact with travelers to areas of ongoing transmission\u2014Continental United States, 2016. MMWR Morb. Mortal Wkly. Rep. 65, 215\u2013216 (2016).","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"656_CR9","doi-asserted-by":"publisher","first-page":"e2636","DOI":"10.1371\/journal.pntd.0002636","volume":"8","author":"O Faye","year":"2014","unstructured":"Faye, O. et al. Molecular evolution of Zika virus during its emergence in the 20(th) century. PLoS Negl. Trop. Dis. 8, e2636 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"656_CR10","doi-asserted-by":"publisher","first-page":"e1477","DOI":"10.1371\/journal.pntd.0001477","volume":"6","author":"AD Haddow","year":"2012","unstructured":"Haddow, A. D. et al. Genetic characterization of Zika virus strains: geographic expansion of the Asian lineage. PLoS Negl. Trop. Dis. 6, e1477 (2012).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"656_CR11","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3201\/eid2205.160065","volume":"22","author":"RS Lanciotti","year":"2016","unstructured":"Lanciotti, R. S., Lambert, A. J., Holodniy, M., Saavedra, S. & Signor Ldel, C. Phylogeny of Zika virus in Western Hemisphere, 2015. Emerg. Infect. Dis. 22, 933\u2013935 (2016).","journal-title":"Emerg. Infect. Dis."},{"key":"656_CR12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/cid\/ciu346","volume":"59","author":"L Liu","year":"2014","unstructured":"Liu, L. Fields virology, 6th Edition. Clin. Infect. Dis. 59, 613 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"656_CR13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.coviro.2012.02.011","volume":"2","author":"TC Pierson","year":"2012","unstructured":"Pierson, T. C. & Diamond, M. S. Degrees of maturity: the complex structure and biology of flaviviruses. Curr. Opin. Virol. 2, 168\u2013175 (2012).","journal-title":"Curr. Opin. Virol."},{"key":"656_CR14","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1126\/science.1153264","volume":"319","author":"IM Yu","year":"2008","unstructured":"Yu, I. M. et al. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 319, 1834\u20131837 (2008).","journal-title":"Science"},{"key":"656_CR15","doi-asserted-by":"publisher","first-page":"e0005608","DOI":"10.1371\/journal.pntd.0005608","volume":"11","author":"H Boigard","year":"2017","unstructured":"Boigard, H. et al. Zika virus-like particle (VLP) based vaccine. PLoS Negl. Trop. Dis. 11, e0005608 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"656_CR16","doi-asserted-by":"publisher","first-page":"13975","DOI":"10.1128\/JVI.78.24.13975-13986.2004","volume":"78","author":"WD Crill","year":"2004","unstructured":"Crill, W. D. & Chang, G. J. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J. Virol. 78, 13975\u201313986 (2004).","journal-title":"J. Virol."},{"key":"656_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0065-3527(03)59002-9","volume":"59","author":"BD Lindenbach","year":"2003","unstructured":"Lindenbach, B. D. & Rice, C. M. Molecular biology of flaviviruses. Adv. Virus Res. 59, 23\u201361 (2003).","journal-title":"Adv. Virus Res."},{"key":"656_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1126\/science.aai9137","volume":"354","author":"KA Dowd","year":"2016","unstructured":"Dowd, K. A. et al. Rapid development of a DNA vaccine for Zika virus. Science 354, 237\u2013240 (2016).","journal-title":"Science"},{"key":"656_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/npjvaccines.2016.21","volume":"1","author":"K Muthumani","year":"2016","unstructured":"Muthumani, K. et al. In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. NPJ Vaccines 1, 16021 (2016).","journal-title":"NPJ Vaccines"},{"key":"656_CR20","doi-asserted-by":"publisher","first-page":"e1003585","DOI":"10.1371\/journal.ppat.1003585","volume":"9","author":"AM Nour","year":"2013","unstructured":"Nour, A. M., Li, Y., Wolenski, J. & Modis, Y. Viral membrane fusion and nucleocapsid delivery into the cytoplasm are distinct events in some flaviviruses. PLoS Pathog. 9, e1003585 (2013).","journal-title":"PLoS Pathog."},{"key":"656_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.chom.2016.04.006","volume":"19","author":"L Wang","year":"2016","unstructured":"Wang, L. et al. From mosquitos to humans: genetic evolution of Zika virus. Cell Host Microbe 19, 561\u2013565 (2016).","journal-title":"Cell Host Microbe"},{"key":"656_CR22","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3201\/eid1408.080287","volume":"14","author":"RS Lanciotti","year":"2008","unstructured":"Lanciotti, R. S. et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg. Infect. Dis. 14, 1232\u20131239 (2008).","journal-title":"Emerg. Infect. Dis."},{"key":"656_CR23","doi-asserted-by":"publisher","first-page":"e0004816","DOI":"10.1371\/journal.pntd.0004816","volume":"10","author":"MC Bonaldo","year":"2016","unstructured":"Bonaldo, M. C. et al. Isolation of infective zika virus from urine and saliva of patients in Brazil. PLoS Negl. Trop. Dis. 10, e0004816 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"656_CR24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nature18625","volume":"535","author":"R Zhang","year":"2016","unstructured":"Zhang, R. et al. A CRISPR screen defines a signal peptide processing pathway required by flaviviruses. Nature 535, 164\u2013168 (2016).","journal-title":"Nature"},{"key":"656_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature20564","volume":"540","author":"G Sapparapu","year":"2016","unstructured":"Sapparapu, G. et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 540, 443\u2013447 (2016).","journal-title":"Nature"},{"key":"656_CR26","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.cell.2016.07.020","volume":"166","author":"H Zhao","year":"2016","unstructured":"Zhao, H. et al. Structural basis of zika virus-specific antibody protection. Cell 166, 1016\u20131027 (2016).","journal-title":"Cell"},{"key":"656_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14722","volume":"8","author":"SS Hasan","year":"2017","unstructured":"Hasan, S. S. et al. A human antibody against Zika virus crosslinks the E protein to prevent infection. Nat. Commun. 8, 14722 (2017).","journal-title":"Nat. Commun."},{"key":"656_CR28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0168-1702(89)90095-6","volume":"12","author":"PL Summers","year":"1989","unstructured":"Summers, P. L., Cohen, W. H., Ruiz, M. M., Hase, T. & Eckels, K. H. Flaviviruses can mediate fusion from without in Aedes albopictus mosquito cell cultures. Virus Res. 12, 383\u2013392 (1989).","journal-title":"Virus Res."},{"key":"656_CR29","doi-asserted-by":"publisher","first-page":"e01559","DOI":"10.1128\/mBio.01559-15","volume":"6","author":"KA Dowd","year":"2015","unstructured":"Dowd, K. A., DeMaso, C. R. & Pierson, T. C. Genotypic differences in Dengue virus neutralization are explained by a single amino acid mutation that modulates virus breathing. mBio 6, e01559\u201301515 (2015).","journal-title":"mBio"},{"key":"656_CR30","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1128\/JVI.72.3.2141-2149.1998","volume":"72","author":"CE Stocks","year":"1998","unstructured":"Stocks, C. E. & Lobigs, M. Signal peptidase cleavage at the flavivirus C-prM junction: dependence on the viral NS2B-3 protease for efficient processing requires determinants in C, the signal peptide, and prM. J. Virol. 72, 2141\u20132149 (1998).","journal-title":"J. Virol."},{"key":"656_CR31","doi-asserted-by":"publisher","first-page":"6218","DOI":"10.1073\/pnas.90.13.6218","volume":"90","author":"M Lobigs","year":"1993","unstructured":"Lobigs, M. Flavivirus premembrane protein cleavage and spike heterodimer secretion require the function of the viral proteinase NS3. Proc. Natl Acad. Sci. USA 90, 6218\u20136222 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"656_CR32","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1128\/jvi.69.4.1995-2003.1995","volume":"69","author":"VF Yamshchikov","year":"1995","unstructured":"Yamshchikov, V. F. & Compans, R. W. Formation of the flavivirus envelope: role of the viral NS2B-NS3 protease. J. Virol. 69, 1995\u20132003 (1995).","journal-title":"J. Virol."},{"key":"656_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.virusres.2016.10.005","volume":"227","author":"ERA Oliveira","year":"2017","unstructured":"Oliveira, E. R. A., Mohana-Borges, R., de Alencastro, R. B. & Horta, B. A. C. The flavivirus capsid protein: structure, function and perspectives towards drug design. Virus Res. 227, 115\u2013123 (2017).","journal-title":"Virus Res."},{"key":"656_CR34","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.antiviral.2009.10.008","volume":"85","author":"SC Weaver","year":"2010","unstructured":"Weaver, S. C. & Reisen, W. K. Present and future arboviral threats. Antiviral Res. 85, 328\u2013345 (2010).","journal-title":"Antiviral Res."},{"key":"656_CR35","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1517\/14712598.5.5.627","volume":"5","author":"AL Szymczak","year":"2005","unstructured":"Szymczak, A. L. & Vignali, D. A. Development of 2A peptide-based strategies in the design of multicistronic vectors. Expert. Opin. Biol. Ther. 5, 627\u2013638 (2005).","journal-title":"Expert. Opin. Biol. Ther."},{"key":"656_CR36","doi-asserted-by":"publisher","first-page":"11540","DOI":"10.1128\/JVI.01745-14","volume":"88","author":"P Scaturro","year":"2014","unstructured":"Scaturro, P. et al. Characterization of the mode of action of a potent dengue virus capsid inhibitor. J. Virol. 88, 11540\u201311555 (2014).","journal-title":"J. Virol."},{"key":"656_CR37","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0966-842X(03)00208-7","volume":"11","author":"R Noad","year":"2003","unstructured":"Noad, R. & Roy, P. Virus-like particles as immunogens. Trends Microbiol. 11, 438\u2013444 (2003).","journal-title":"Trends Microbiol."},{"key":"656_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coviro.2016.03.001","volume":"18","author":"KM Frietze","year":"2016","unstructured":"Frietze, K. M., Peabody, D. S. & Chackerian, B. Engineering virus-like particles as vaccine platforms. Curr. Opin. Virol. 18, 44\u201349 (2016).","journal-title":"Curr. Opin. Virol."},{"key":"656_CR39","doi-asserted-by":"publisher","unstructured":"Garg, H., Sedano, M., Plata, G., Punke, E. B. & Joshi, A. Development of virus-like-particle vaccine and reporter assay for Zika virus. J. Virol. 91, https:\/\/doi.org\/10.1128\/JVI.00834-17 (2017).","DOI":"10.1128\/JVI.00834-17"},{"key":"656_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61103-1","volume":"10","author":"H Garg","year":"2020","unstructured":"Garg, H., Mehmetoglu-Gurbuz, T. & Joshi, A. Virus like particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus. Sci. Rep. 10, 4017 (2020).","journal-title":"Sci. Rep."},{"key":"656_CR41","doi-asserted-by":"publisher","first-page":"e0202820","DOI":"10.1371\/journal.pone.0202820","volume":"13","author":"F Cox","year":"2018","unstructured":"Cox, F. et al. Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge. PLoS ONE 13, e0202820 (2018).","journal-title":"PLoS ONE"},{"key":"656_CR42","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.aah6157","volume":"353","author":"P Abbink","year":"2016","unstructured":"Abbink, P. et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353, 1129\u20131132 (2016).","journal-title":"Science"},{"key":"656_CR43","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature18952","volume":"536","author":"RA Larocca","year":"2016","unstructured":"Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nature 536, 474\u2013478 (2016).","journal-title":"Nature"},{"key":"656_CR44","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-1-4939-6481-9_6","volume":"1499","author":"N Pardi","year":"2017","unstructured":"Pardi, N. & Weissman, D. Nucleoside modified mRNA vaccines for infectious diseases. Methods Mol. Biol. 1499, 109\u2013121 (2017).","journal-title":"Methods Mol. Biol."},{"key":"656_CR45","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/psc.836","volume":"13","author":"M Manea","year":"2007","unstructured":"Manea, M., Mezo, G., Hudecz, F. & Przybylski, M. Mass spectrometric identification of the trypsin cleavage pathway in lysyl-proline containing oligotuftsin peptides. J. Pept. Sci. 13, 227\u2013236 (2007).","journal-title":"J. Pept. Sci."},{"key":"656_CR46","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines\u2014a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"656_CR47","doi-asserted-by":"publisher","unstructured":"Maciejewski, S. et al. Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. Sci. Transl. Med. 12, https:\/\/doi.org\/10.1126\/scitranslmed.aaw9066 (2020).","DOI":"10.1126\/scitranslmed.aaw9066"},{"key":"656_CR48","doi-asserted-by":"publisher","unstructured":"Essink, B. et al. The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials. Lancet Infect. Dis., https:\/\/doi.org\/10.1016\/S1473-3099(22)00764-2 (2023).","DOI":"10.1016\/S1473-3099(22)00764-2"},{"key":"656_CR49","doi-asserted-by":"publisher","first-page":"eaaz6893","DOI":"10.1126\/sciadv.aaz6893","volume":"6","author":"J Nelson","year":"2020","unstructured":"Nelson, J. et al. Impact of mRNA chemistry and manufacturing process on innate immune activation. Sci. Adv. 6, eaaz6893 (2020).","journal-title":"Sci. Adv."},{"key":"656_CR50","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","volume":"26","author":"S Sabnis","year":"2018","unstructured":"Sabnis, S. et al. A Novel Amino Lipid Series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol. Ther. 26, 1509\u20131519 (2018).","journal-title":"Mol. Ther."},{"key":"656_CR51","doi-asserted-by":"publisher","first-page":"7394","DOI":"10.1016\/j.vaccine.2021.11.001","volume":"39","author":"K Wu","year":"2021","unstructured":"Wu, K. et al. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. Vaccine 39, 7394\u20137400 (2021).","journal-title":"Vaccine"},{"key":"656_CR52","doi-asserted-by":"publisher","first-page":"111299","DOI":"10.1016\/j.celrep.2022.111299","volume":"40","author":"AC Walls","year":"2022","unstructured":"Walls, A. C. et al. Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice. Cell Rep. 40, 111299 (2022).","journal-title":"Cell Rep."},{"key":"656_CR53","doi-asserted-by":"publisher","unstructured":"Scheaffer, S. M. et al. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice. Nat. Med., https:\/\/doi.org\/10.1038\/s41591-022-02092-8 (2022).","DOI":"10.1038\/s41591-022-02092-8"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00656-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00656-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00656-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T18:13:07Z","timestamp":1682014387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00656-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["656"],"URL":"https:\/\/doi.org\/10.1038\/s41541-023-00656-4","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"12 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.B., N.N., K.B., C.J.H., H.B., and A.C. are employees of Moderna, Inc., and hold stock\/stock options in the company. T.C.P., K.A.D., B.S.G., and W.-P.K. are inventors on patent applications describing the VRC5283 DNA vaccine (U.S. patent application number 16\/334,099 and PCT\/2018\/018809). TCP is supported by the Division of Intramural Research, NIAID, NIH. S.B., B.F., K.E.B., M.A., B.E.F., T.J.R., and K.M.M. have no conflicts.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}